By MArK L. FUerst received definitive platinum-based chemoradiotherapy. Patients were
randomly assigned to receive osimertinib (143 patients) or a placebo (73 patients). Median …

Osimertinib significantly improves progression-free survival (PFS) in patients with
unresectable Stage III EGFR-mutated non-small cell lung cancer (NSCLC) following …